Named Patient Program With Rotigotine Transdermal System
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The named patient program will allow investigators to supply rotigotine transdermal system to
patients who have a documented medical necessity to receive treatment with the drug.